Eli Lilly's anti-tumor drug Verzenio achieved positive results in a Phase III trial, significantly improving the survival rates of specific breast cancer patients.

According to the financial and economic app of Wisdom Finance, Eli Lilly (LLY.US) announced important news on Wednesday that its anti-tumor drug Verzenio achieved breakthrough progress in late-stage clinical trials. According to the primary overall survival (OS) analysis data of the global phase III monarchE trial, this FDA-approved drug as part of combination therapy significantly improved the overall survival rate of specific breast cancer patients.